1 Jan 2016 Jahr - Pembrolizumab extends NSCLC survival, with fewer side effects
Beschreibung:
Pembrolizumab improves survival and causes fewer side effects than standard chemotherapy for patients.
Zugefügt zum Band der Zeit:
Datum:
~ 8 years and 5 months ago